Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

CytRx Corp (NASDAQ:CYTR)

1.91
Delayed Data
As of Dec 11
 -0.06 / -3.05%
Today’s Change
1.71
Today|||52-Week Range
5.99
-14.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$54.4M

Company Description

CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It focuses on discovering, developing, and commercializing new therapeutics to treat patients with cancer; including aldoxorubicin, a modified version of the widely-used chemotherapeutic agent, doxorubicin. The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Contact Information

CytRx Corp.
11726 San Vicente Boulevard
Los Angeles California 90049
P:(310) 826-5648
Investor Relations:

Employees

Shareholders

Mutual fund holders0.00%
Other institutional0.00%
Individual stakeholders--

Top Executives

Steven A. KriegsmanChairman, President & Chief Executive Officer
John Y. CalozChief Financial Officer & Treasurer
Felix KratzVice President-Drug Discovery
David J. HaenVP-Business Development & Investor Relations